Argenx has been making significant strides with positive outcomes from several pipeline developments and drug approvals. Their drug,
Vyvgart, has broadened its patient population and received several approvals, including from the
FDA and
NMPA for the treatment of rare nerve disease
CIDP and
gMG. Despite competition from J&J, it seems Argenx has managed to hold its own.
ARGX's stocks have seen notable improvement translating into raised price targets by JPMorgan, among others. Despite this, challenges were met in the form of
failed studies for the clinical development of
efgartigimod in AAV and a skin blistering condition. Argenx reported strong Q2 sales and has projected a 'Vision 2030'. However, there have been varying analyst ratings and the company did experience a 23% pullback in Q4. Despite these hurdles,
ARGX stock continues to trade higher indicating continued investor confidence.
argenx News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Sat, 24 Aug 2024 08:38:34 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 5
